Subsequent Events	9 Months Ended
Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 13—Subsequent events [A] Sumitomo loan agreement amendment and funding On February 5, 2021, the Company and Sumitomo Dainippon Pharma entered into an amendment to the Sumitomo Loan Agreement in which the maximum principal amount available to the Company to borrow pursuant to the terms of the Sumitomo Loan Agreement was increased by $125.0 million to a total of $425.0 million (see Note 5). In January 2021, the Company received gross proceeds of $58.0 million pursuant to a draw under the Sumitomo Loan Agreement (see Note 5). Subsequent to this draw, $267.5 million was outstanding under the Sumitomo Loan Agreement and $157.5 million of borrowing capacity, which includes the increase from the Sumitomo Loan Agreement amendment, remained available to the Company, which amount may be drawn down by the Company, upon request, no more than once in any calendar quarter, pursuant to funding requests by the Company that are made in accordance with the Company’s Board-approved operating budget.

Subsequent Events

9 Months Ended

Dec. 31, 2020

Note 13—Subsequent events

[A] Sumitomo loan agreement amendment and funding

On February 5, 2021, the Company and Sumitomo Dainippon Pharma entered into an amendment to the Sumitomo Loan Agreement in which the maximum principal amount available to the Company to borrow pursuant to the terms of the Sumitomo Loan Agreement was increased by $125.0 million to a total of $425.0 million (see Note 5).

In January 2021, the Company received gross proceeds of $58.0 million pursuant to a draw under the Sumitomo Loan Agreement (see Note 5). Subsequent to this draw, $267.5 million was outstanding under the Sumitomo Loan Agreement and $157.5 million of borrowing capacity, which includes the increase from the Sumitomo Loan Agreement amendment, remained available to the Company, which amount may be drawn down by the Company, upon request, no more than once in any calendar quarter, pursuant to funding requests by the Company that are made in accordance with the Company’s Board-approved operating budget.

Urovant Sciences Ltd. 10-Q